Procter and Gamble Health Q2 Results FY27 Preview: Results Date, Expectations and the Numbers That Will Decide the September 2026 Quarter
- September 11, 2026
- Posted by: Harsh Piplani
- Category: Results
Procter and Gamble Health share price Rs 5,416.50 on 11 September 2026, down 1.00%. Q2 FY27 results date not confirmed. Q1 FY27 net profit Rs 96.00 crore. Q2 FY26 base a profit of Rs 89.00 crore.
Quick Answer
The Procter and Gamble Health Q2 results date for FY27 is not confirmed, and Procter and Gamble Health Ltd. had not filed a board meeting intimation with the NSE or BSE as of 11 September 2026. Indian listing rules require the September 2026 quarter results to be published within 45 days of the quarter end, an outer deadline of 14 November 2026. The quarter will be measured against a September 2025 base of Rs 325.00 crore in revenue and a profit of Rs 89.00 crore. This preview uses reported actuals only and carries no estimated revenue or profit figure for the coming quarter.
The Procter and Gamble Health Q2 results FY27 announcement is the next scheduled earnings event for Procter and Gamble Health Ltd., the vitamins, minerals and supplements arm of Procter and Gamble in India, selling Neurobion, Livogen, Nasivion, Seven Seas and related brands through pharmacy and prescription channels. The stock traded at Rs 5,416.50 on the NSE on 11 September 2026, down 1.00% from the previous close of Rs 5,471.20, about 21.5% below its 52-week high of Rs 6,900.00 and 20.4% above its 52-week low of Rs 4,500.10.
What makes the Procter and Gamble Health Q2 results print worth watching is the base it faces. The September 2025 quarter delivered Rs 325.00 crore of revenue and a profit of Rs 89.00 crore, while the most recent quarter on record, Q1 FY27, produced Rs 364.00 crore and a profit of Rs 96.00 crore. Everything below is built from those reported figures rather than from any forecast.
Click Here – Get Free Investment Predictions
When Is the Procter and Gamble Health Q2 Results FY27 Date?
The Procter and Gamble Health Q2 results date for FY27 is not confirmed. As of 11 September 2026, Procter and Gamble Health Ltd. had not filed a board meeting intimation with the NSE or BSE for the September 2026 quarter, so any date circulating before that filing appears should be treated as unverified.
What can be stated is the regulatory boundary. Listed companies in India must publish quarterly results within 45 days of the end of the quarter, which places the outer deadline for the September 2026 quarter at 14 November 2026. Companies also have to give the exchanges prior intimation of the board meeting that approves the results, so the Procter and Gamble Health Q2 results date becomes public through that filing rather than through any advance announcement.
The Procter and Gamble Health Q2 results FY27 print covers 1 July 2026 to 30 September 2026. Small and mid-cap companies more often report in the second half of that window than in the first, so late October or early November is the range to watch for Procter and Gamble Health.
Procter and Gamble Health Q2 Results Expectations: What the Market Is Actually Tracking
No verified analyst estimate for the Procter and Gamble Health Q2 results FY27 quarter is in the public domain, so no revenue or profit figure should be assumed for Procter and Gamble Health. The Procter and Gamble Health Q2 results watchlist below is built from what the company has actually reported and disclosed.
The first is revenue, which was Rs 325 crore in September 2025, the lowest of the five quarters, against Rs 364 crore in Q1 FY27, a rise of about 12%. Sales have otherwise been broadly flat in a Rs 325 crore to Rs 374 crore band.
The second is the operating margin, which was 37% in September 2025 and 27% in Q1 FY27. Margin oscillates between 27% and 37% quarter to quarter on almost unchanged revenue, which points at lumpy cost phasing rather than a trend.
The third is that the June 2026 quarter is flattered from below the operating line. Other income jumped to Rs 36 crore from a Rs 4 crore to Rs 5 crore run rate, supplying 28% of pre-tax profit, which is why net profit was the highest of the window even though operating profit fell 26%.
Check Procter and Gamble Health Ltd. Live Fundamentals on the Univest Screener
Procter and Gamble Health Q2 Results Preview: The Q1 FY27 Actuals It Builds On
Procter and Gamble Health Ltd. reported revenue of Rs 364.00 crore in Q1 FY27, up 7.37% from Rs 339.00 crore in Q1 FY26, and a profit of Rs 96.00 crore at the net level, up 45.45% from Rs 66.00 crore in Q1 FY26. These are reported actuals, not estimates.
Sequentially, revenue was down 1.62% over the March 2026 quarter figure of Rs 370.00 crore, and net profit was up 1.05% from Rs 95.00 crore in Q4 FY26. Operating margin stood at 27% in Q1 FY27 against 37% in the September 2025 quarter, which is the comparison the Procter and Gamble Health Q2 results print will be read against.
Q2 FY26 Base: The Comparison Procter and Gamble Health Q2 Results FY27 Must Beat
Procter and Gamble Health Ltd. reported revenue of Rs 325.00 crore and a profit of Rs 89.00 crore in Q2 FY26, the September 2025 quarter. That is the year-ago base against which the September 2026 numbers will be judged, and it is the single most useful figure in this Procter and Gamble Health Q2 results preview.
Net profit in that base quarter was below the Rs 96.00 crore just reported for Q1 FY27, so the year-on-year comparison starts from a manageable level. Revenue of Rs 325.00 crore sits below the Rs 364.00 crore of the June 2026 quarter, which frames how much sequential movement the Procter and Gamble Health Q2 results print needs to show growth.
Procter and Gamble Health Quarterly Results Trend Over the Last Four Quarters
| Quarter | Revenue (Rs Cr) | Net Profit (Rs Cr) |
|---|---|---|
| Q2 FY26 (Sep 2025) | 325.00 | 89.00 |
| Q3 FY26 (Dec 2025) | 374.00 | 78.00 |
| Q4 FY26 (Mar 2026) | 370.00 | 95.00 |
| Q1 FY27 (Jun 2026) | 364.00 | 96.00 |
Figures in brackets denote negative numbers. All four quarters above are reported actuals taken from the company’s exchange filings, and they are the only basis this Procter and Gamble Health Q2 results preview uses.
Revenue across those four quarters ranged from Rs 325.00 crore to Rs 374.00 crore, and net profit from Rs 78.00 crore to Rs 96.00 crore. That spread is the honest context for the Procter and Gamble Health Q2 results FY27 print, and it is why a single quarter should not be read as a trend on its own.
Key Factors That Could Shape Procter and Gamble Health Q2 Results FY27
The Procter and Gamble Health Q2 results outcome will turn on a small number of company-specific variables rather than on broad market conditions. The three below are the ones visible in what Procter and Gamble Health has already reported.
Prescription Habit Drives the Brands
Neurobion and Livogen are prescribed rather than bought on impulse, so volume follows doctor prescribing habits and pharmacy stocking rather than advertising. That makes the revenue line stable but slow to change direction.
The Capital Base Is Deliberately Small
Reserves of Rs 508 crore and Rs 9 crore of borrowings against a 2.86% dividend yield are what produce a return on equity of 61.9% and return on capital employed of 83.9%. Those ratios describe a high-payout policy, not an unusually profitable business.
The Fiscal Year Is Now April to March
The company completed its move off the old July to June year through a nine-month transition period ended March 2025, so the September 2026 quarter is genuinely its second quarter of FY27. All five quarters used here are ordinary three-month periods.
Procter and Gamble Health Q2 Results FY27: Share Price and Valuation Going Into the Print
Procter and Gamble Health share price today is Rs 5,416.50 on the NSE, down Rs 54.70 or 1.00% from the previous close of Rs 5,471.20 on 11 September 2026, ahead of the Procter and Gamble Health Q2 results announcement.
| Metric | Value (11 September 2026) |
|---|---|
| NSE Symbol | PGHL |
| Current Market Price | Rs 5,416.50 |
| 52-Week High | Rs 6,900.00 |
| 52-Week Low | Rs 4,500.10 |
| Market Capitalisation | Rs 8,988 crore |
| PE Ratio | 26.95 |
| PB Ratio | 17.14 |
| EPS (TTM) | Rs 200.96 |
| Book Value per Share | Rs 316.00 |
| Debt to Equity | 0.02 |
| Return on Equity | 61.9% |
| 50-Day Moving Average | Rs 6,184.58 |
| 200-Day Moving Average | Rs 5,638.70 |
| RSI (14) | 23.37 |
The stock trades below both its 50-day average of Rs 6,184.58 and its 200-day average of Rs 5,638.70, with a 14-day RSI of 23.37. None of this is a view on where the shares go once the Procter and Gamble Health Q2 results are announced, and no price target is offered here.
Download the Univest iOS App or Univest Android App to track Procter and Gamble Health Ltd. live price and quarterly earnings updates.
What Investors Should Watch When Procter and Gamble Health Q2 Results Are Announced
Four lines carry most of the information in a company of this size, and reading them in order keeps the Procter and Gamble Health Q2 results print in proportion.
- Revenue against the Rs 325.00 crore reported in the September 2025 base quarter
- Net profit against a profit of Rs 89.00 crore in that same quarter
- Operating margin against 27% in Q1 FY27
- Any exceptional item, provision or one-off gain disclosed alongside the numbers
A one-off gain or provision can move the reported profit far more than operations do in a company this size, which is why the Procter and Gamble Health Q2 results announcement should be read together with the notes to the results rather than the headline alone.
Conclusion on Procter and Gamble Health Q2 Results FY27
The Procter and Gamble Health Q2 results date is not confirmed, and 14 November 2026 is the statutory outer limit rather than an expected date. Procter and Gamble Health Ltd. will make the schedule public through a board meeting intimation to the exchanges, and until then the September 2026 quarter can only be framed by what has already been reported.
On that basis the Procter and Gamble Health Q2 results FY27 print faces a base of Rs 325.00 crore in revenue and a profit of Rs 89.00 crore, with the most recent quarter having delivered Rs 364.00 crore and a profit of Rs 96.00 crore. No numerical estimate appears in this preview because no verified consensus figure exists for Procter and Gamble Health, and readers should treat any preview that supplies one with caution. Verify every figure against the company filing on release and consult a SEBI-registered advisor before acting on quarterly earnings.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
FAQs on Procter and Gamble Health Q2 Results FY27
What is the Procter and Gamble Health Q2 results date for FY27?
Ans. The Procter and Gamble Health Q2 results date for FY27 is not confirmed. Procter and Gamble Health Ltd. had not filed a board meeting intimation with the NSE or BSE as of 11 September 2026. Indian listing rules require the September 2026 quarter results to be published by 14 November 2026 at the latest.
What quarter do the Procter and Gamble Health Q2 results 2026 cover?
Ans. The Procter and Gamble Health Q2 results FY27 cover 1 July 2026 to 30 September 2026, known as the September 2026 quarter. Procter and Gamble Health Ltd. reports revenue, operating profit and net profit for that period, and the Procter and Gamble Health Q2 results filing also carries the notes to the accounts.
What were the Procter and Gamble Health Q1 FY27 results?
Ans. Procter and Gamble Health Ltd. reported revenue of Rs 364.00 crore in Q1 FY27 and a profit of Rs 96.00 crore at the net level. Revenue was up 7.37% versus Q1 FY26 and net profit was up 45.45% from Rs 66.00 crore in Q1 FY26.
What were Procter and Gamble Health Q2 FY26 results in the September 2025 quarter?
Ans. Procter and Gamble Health Ltd. reported revenue of Rs 325.00 crore and a profit of Rs 89.00 crore in Q2 FY26. Operating margin was 37%. Those figures form the base for the Procter and Gamble Health Q2 results FY27 comparison.
What are the main Procter and Gamble Health Q2 results expectations this quarter?
Ans. No verified analyst estimate is publicly available. The Procter and Gamble Health Q2 results expectations centre on revenue against the Rs 325.00 crore base, net profit against a profit of Rs 89.00 crore, operating margin against 27% in Q1 FY27, and any exceptional item disclosed with the numbers.
What is Procter and Gamble Health share price today ahead of the Q2 earnings?
Ans. Procter and Gamble Health share price is Rs 5,416.50 on the NSE as of 11 September 2026, down 1.00% from Rs 5,471.20. The stock is about 21.5% below its 52-week high of Rs 6,900.00 and 20.4% above its 52-week low of Rs 4,500.10, at a market capitalisation of Rs 8,988 crore.
Is Procter and Gamble Health a good stock to buy before the Q2 results?
Ans. This article does not offer a buy, sell or hold recommendation on Procter and Gamble Health Ltd. The stock trades at a price-to-book ratio of 17.14 with a return on equity of 61.9%. Assess the reported numbers when they are released and consult a SEBI-registered financial advisor before making any decision.
